ライフサイエンスコーパス: sargramostim

1 aIota, remained stable in subjects receiving sargramostim.

2 mumab, 10 mg/kg, intravenously on day 1 plus sargramostim, 250 mug subcutaneously, on days 1 to 14 of

3 load excluded any 0.5 log10 increase due to sargramostim (95% confidence interval, -0.68 to 0.44).

4 sargramostim and filgrastim were superior to sargramostim alone for the mobilization of CD34(+) cells

5 s of filgrastim, sargramostim, or sequential sargramostim and filgrastim on CD34(+) cell yields and m

6 oncluded that filgrastim alone or sequential sargramostim and filgrastim were superior to sargramosti

7 ints in the CDAI score on day 57 between the sargramostim and placebo groups (54 percent vs. 44 perce

8 nswered question is whether systemic GM-CSF (sargramostim) enhances CTLA-4 blockade.

9 lgrastim (n = 51), sargramostim (n = 52), or sargramostim for 5 days followed by filgrastim (n = 53)

10 acrophage colony-stimulating factor (GM-CSF; sargramostim) for malignant liver tumors, predominantly

11 once every 2 weeks) in Montanide ISA-51 plus sargramostim (granulocyte macrophage colony-stimulating

12 Sargramostim, granulocyte-macrophage colony-stimulating

13 The sargramostim group also had significant improvements in

14 f remission were significantly higher in the sargramostim group than in the placebo group on day 29 o

15 However, significantly more patients in the sargramostim group than in the placebo group reached the

16 8%-54.4%) of patients in the ipilimumab plus sargramostim group vs 58.3% (95% CI, 49.0%-67.2%) of pat

17 ctions and bone pain were more common in the sargramostim group, and three patients in this group had

18 Sargramostim is a yeast-derived, recombinant human granu

19 GM-CSF (sargramostim) is approved for neutropenia associated wit

20 Recombinant human GM-CSF (rHuGMCSF) (sargramostim [Leukine]) is an FDA-approved drug used to

21 Preliminary studies suggest sargramostim may have activity in Crohn's disease.

22 ansfusions (P =.001) than patients receiving sargramostim-mobilized PBSCs.

23 e randomized to receive filgrastim (n = 51), sargramostim (n = 52), or sargramostim for 5 days follow

24 , including indinavir or ritonavir, received sargramostim or placebo 3 times a week for 8 weeks.

25 dy was to compare the effects of filgrastim, sargramostim, or sequential sargramostim and filgrastim

26 Compared with those who received sargramostim, patients who received filgrastim had faste

27 e active Crohn's disease to receive 6 mug of sargramostim per kilogram per day or placebo subcutaneou

28 gs for the secondary end points suggest that sargramostim therapy decreased disease severity and impr

29 harmacokinetics was observed before or after sargramostim therapy.

30 Sargramostim treatment was associated with a trend towar

31 IV melanoma, treatment with ipilimumab plus sargramostim vs ipilimumab alone resulted in longer OS a

32 n OS as of December 2012 for ipilimumab plus sargramostim was 17.5 months (95% CI, 14.9-not reached)

33 Median PFS for ipilimumab plus sargramostim was 3.1 months (95% CI, 2.9-4.6) vs 3.1 mon

34 The 1-year survival rate for ipilimumab plus sargramostim was 68.9% (95% CI, 60.6%-85.5%) compared to

35 Sargramostim was well tolerated, and inflammatory cytoki